|  Home  |  Lunenfeld-Tanenbaum  |  RTC  |  sciHigh  |  Hospital  |  Foundation  |
  Site Map    Contacts  

Mount Sinai Hospital

 University of Toronto

Darlene Homonko - Director

ext. 6380

Dr. Homonko has over fifteen years experience in life sciences commercialization with specific experience in early stage company formation. Prior to joining Mount Sinai Hospital, Dr. Homonko was Director of Business Development at Vineland Research and Innovation Centre in Vineland Ontario. A natural at engaging people and developing partnerships, she spearheaded the formation of a vibrant bioscience cluster in Hamilton, Halton and Niagara as the Executive Director of the Golden Horseshoe Bioscience Network (GHBN) for five years. Managing a multi-stakeholder contribution of just under 2 million dollars, she and her team created new programs and connections that continue to impact the region. With her expertise and guidance, the network was instrumental in helping companies grow and access the knowledge and financial resources they needed to be successful and competitive.

Dr. Homonko began her career as a key member of an investment team that managed a US$20 million early stage Canadian Biomedical Venture Fund. During her tenure at Milestone Medica Corporation’s (MMC) she was seconded to the post of Director of Operations and Business Development for one of MMC’s companies – Molecular Templates Inc. (MTI), that was developing anti-cancer therapeutics from bacterial proteins. Following MTI, Dr. Homonko held a senior management post as an Industry Liaison Officer at the University of Toronto Innovations Foundation where she focused on identifying new spin-out opportunities in the life science and convergent medical technologies sector. 

In possession of a strong background in intellectual property management, technology evaluation and analyzing corporate research and development in commercial alliances for sound business practice, Dr. Homonko holds a Ph.D., Neuroscience from the University of Toronto, Institute of Medical Sciences; a M.Sc., Kinesiology from Dalhousie University; and a B.Sc., Physical Education, Health, General Science from the University of Rhode Island.


Chantal Lackan - Contracts Coordinator 



Linda Kurdydyk - Patent Counsel

ext. 3235

Linda has been retained on a part-time basis since 1996 as Patent Counsel for Mount Sinai Hospital and the Lunenfeld-Tanenbaum Research Institute. Ms Kurdydyk also acts as patent counsel to a local drug discovery company, Transition Therapeutics. Linda has previously been a partner in major intellectual property law firms. As in-house patent counsel for the Office of Technology Transfer & Industrial Liaison she has responsibility for evaluating, and protecting discoveries with commercial applications and providing legal advice and business guidance on a variety of issues arising out of the activities of the Office of Technology Transfer & Industrial Liaison.

Ms Kurdydyk has an MSc in Microbiology from the University of Manitoba, is a registered Canadian and US Patent Agent and has extensive experience in drafting and prosecuting biomedical patents for a spectrum of corporate and academic clients as well as drafting and negotiating license, research and consulting agreements. 


Zoe Ramirez-Reeves - Research Counsel

ext. 7646


Konrad Powell-Jones - Project Manager

ext. 5955

Konrad is retained part time on contract to the Office of Technology Transfer & Industrial Liaison. Konrad brings a strong scientific foundation and extensive sales and marketing experience in the pharmaceutical industry as well as drawing on experience gained in his more than 16 years in the academic technology commercialization environment in his roles as a commercialization consultant at various Toronto based institutions such as Mount Sinai Hospital; Canadian Arthritis Network; Innovations at University of Toronto; the former Sunnybrook & Women’s College Health Science Centre; the Hospital for Sick Children and the Centre for Addiction & Mental Health. Konrad has responsibility for the evaluation and marketing of discoveries and research opportunities and the negotiation of confidentiality, license, research and interinstitutional agreements in connection with joint inventions and research collaborations.


Michael Hanna - Sr. Business Development Officer

ext. 4752

Michael brings to the OTTIL over fifteen years technology transfer experience, three of which were spent on the industry side in his role as Technology Transfer Administrator for Regeneron Pharmaceuticals, Inc. (Tarrytown, New York), where he acted as the liaison between the company and the scientific community, establishing and maintaining research collaborations with outside investigators. He has a B.Sc. (honours) in Biology from the University of Waterloo and a M.Sc. in molecular microbiology from the University of Toronto, Faculty of Dentistry. Michael is responsible for a variety of matters including review and negotiation of material transfer agreements, industry-sponsored research agreements, evaluating invention disclosures and other opportunities, marketing, license negotiation and license monitoring.